| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6 and 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | buprenorphine / naloxone (Zubsolv®) |
| Formulation | 0.7 mg / 0.18 mg, 1.4 mg / 0.36 mg, 2.9 mg / 0.71 mg, 5.7 mg / 1.4 mg, 8.6 mg / 2.1 mg and 11.4 mg / 2.9 mg sublingual tablet |
| Reference number | 3386 |
| Indication | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction. |
| Company | Mundipharma Corporation Ltd. |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 09/12/2021 |